BY9010/M1‐137.

Methods	STUDY DESIGN: Parallel group LOCATION, NUMBER OF CENTRES: 9 centres in Taiwan and Malaysia DURATION OF STUDY: 12 weeks (prn SABA) CONCEALMENT OF ALLOCATION: Not clear COCHRANE QUALITY SCORE: B DESCRIBED AS RANDOMISED: Yes DESCRIBED AS DOUBLE BLIND: Yes METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: Not reported METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: Double‐dummy DESCRIPTION OF WITHDRAWALS/DROPOUTS: Not reported JADAD SCORE (5‐1): 3 TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): Per protocol and ITT COMPLIANCE: Not assessed CONFOUNDERS: Groups balanced at baseline
Participants	N SCREENED: Not reported N RANDOMISED: 125 N COMPLETED: Not reported M = not reported F = not reported MEAN AGE: 48 BASELINE DETAILS: FEV1 72% predicted INCLUSION CRITERIA: 18‐ 75 years; ATS defined asthma for at least 6 months; treatment with ICS for 4 weeks (maximum 250mcg fluticasone propionate or equivalent); FEV1 80‐105% of predicted.
Interventions	1. Ciclesonide 200 mcg OD 2. Budesonide 400 mcg OD DELIVERY: Ciclesonide: MDI; Budesonide: Turbohaler TREATMENT PERIOD: 12 weeks RESCUE: Salbutamol CO‐INTERVENTIONS PERMITTED: prn SABA CO‐INTERVENTIONS: Not reported % on ICS at baseline: 100
Outcomes	FEV1; FVC; symptoms; adverse events
Notes	Unpublished data set available from http://www.clinicalstudyresults.org
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear